N/A
Completed N=13
The Efficacy of Hand Narrow-Band Ultraviolet B (NBUVB) Versus Excilite Treatment in Vitiligo After Minigrafting on the Dorsal Hands
Source: ClinicalTrials.gov NCT00622180 ↗Enrolled (actual)
13
Serious AEs
0.0%
Results posted
Nov 2019
Primary outcomePrimary: Percent Repigmentation of Target Lesion — 0.21; 0.17 percentage of repigmentation
Summary
To assess over a 25-week period the efficacy of hand-foot narrow-band ultraviolet B light versus focal 308-nm light treatment in inducing the return of pigment in vitiligo after skin minigraft transplants to the backs of the hands in patients with light brown to black skin. Subject will undergo treatment for 13 weeks.
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Percent Repigmentation of Target Lesion |
0.21; 0.17 | — |
Eligibility Criteria
Inclusion Criteria
- male and female subjects 18 years of age or older
- skin type III-VI
- vitiligo on both dorsal hands
- history of stable vitiligo ( no new lesions and no more than 10% enlargement of existing lesions) for six months with an absence of Kebner phenomenon (new lesions appearing after trauma to the skin)
- refractory to topical steroids and immunomodulators
Exclusion Criteria
- pregnant and/or breast-feeding females
- history of skin cancer
- history of taking photosensitizing medications
- history of recent phototherapy (light therapy) or topical medications within one month prior to enrollment
- history of organ transplantation
- history of failed vitiligo skin transplantation
- history of segmental vitiligo
- history of 12 or more continuous light treatments
Data sourced from ClinicalTrials.gov (NCT00622180). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.